About
Lycia Therapeutics, Inc.
Lycia Therapeutics, Inc., a biotechnology company, engages in the discovery and development of therapeutics designed to degrade disease-causing extracellular proteins for the treatment of autoimmune, inflammatory, and allergic diseases.
The company develops the LYTAC platform, a modular technology designed to create therapeutics that selectively reduce the levels of pathogenic proteins. Its therapeutic candidate LCA-0061 degrades immunoglobulin E (IgE) for the treatment of allergic diseases, including food allergy.
Lycia Therapeutics, Inc. Overview
Ticker, listing venue and issuer profile
Offer & Key Dates
Pricing terms and IPO milestones
Change from offer price to today
Live Market Snapshot
Real-time price; headline % change is vs first trade (listing price)
USD · NASDAQ:NASDAQ:LYCA
Valuation & Multiples
Key valuation ratios and metrics
Financial Health
Balance sheet strength and liquidity
Financial Highlights
Historical financial performance
Historical Data
Market history and supplemental quote data
| Date | Open | High | Low | Close | Adj. Close | Change | Volume |
|---|---|---|---|---|---|---|---|
| 2026-10-30 | $27.17 | $27.59 | $25.66 | $26.40 | $26.40 | -0.77 | 202,400 |
| 2026-10-29 | $25.25 | $27.83 | $24.51 | $27.73 | $27.73 | +2.48 | 173,100 |
| 2026-10-28 | $26.48 | $26.48 | $24.03 | $25.05 | $25.05 | -1.43 | 433,100 |
| 2026-10-27 | $26.51 | $28.00 | $24.63 | $26.11 | $26.11 | -0.40 | 426,800 |
| 2026-10-26 | $23.73 | $30.91 | $23.73 | $28.85 | $28.85 | +5.12 | 965,500 |
| 2026-10-23 | $28.55 | $36.49 | $22.19 | $30.00 | $30.00 | +1.45 | 2,284,000 |
SEC Filings
Official documents from SEC EDGAR
| Form | Filing Date | Document |
|---|---|---|
| SCHEDULE 13G | Oct 30, 2026 | Filing |
| 8-K | Oct 26, 2026 | Current Report |
| S-8 | Oct 23, 2026 | Securities to be offered to employees in employee benefit plans |
| 424B4 | Oct 23, 2026 | Prospectus |
| EFFECT | Oct 22, 2026 | Notice of Effectiveness |
| S-1MEF | Oct 22, 2026 | Registration adding securities to prior Form S-1 registration |
| CERT | Oct 22, 2026 | Certification by an exchange approving securities for listing |
| 8-A12B | Oct 20, 2026 | Registration of securities |
| S-1/A | Oct 20, 2026 | [Amend] General form for registration of securities under the Securities Act of 1933 |
| S-1 | Oct 5, 2026 | General form for registration of securities under the Securities Act of 1933 |
Company Info
Contact and headquarters details
Leadership
Key executives and officers
Aetna Wun Trombley, Ph.D.
President, Chief Executive Officer and Director
Amy Bachrodt
Chief Financial Officer
Chin Lee, M.D.
Chief Medical Officer
Steve Staben, Ph.D.
Chief Scientific Officer
Sofia Touami, Ph.D.
Chief Business Officer
William J. Rieflin
Chair and Director
Tim Anderson
Director
Ming Fang
Director
Laurent Fischer, M.D.
Director
Jane Pritchett Henderson
Director
